Study drug for advanced cancers with specific MAPK changes
Part of Cancer clinical trials.
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (spread or locally advanced) that is getting worse.
- Tumor testing from the past 5 years shows a MAPK pathway gene mutation (Part 1) or a KRAS G12C mutation (Part 2).
- For non-small cell lung cancer (Part 2), your tumor must NOT have certain other gene changes like EGFR, ALK/ROS1/RET, NTRK, BRAF V600E, or MET exon 14 skipping.
- You’ve tried standard treatments—Part 1 means standard treatment is no longer working, not tolerated, or not available; Part 2 requires at least one prior systemic treatment (including a KRAS G12C drug).
- You must have “measurable disease” on scans (Part 2), plus provide tumor tissue (archival or optional fresh biopsy) and blood for genetic testing.
- Your health status is high enough to participate (ECOG 0–1) and your organs are functioning adequately; you must also follow birth control/reproductive rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial tests a new medicine called D3S-003 in people whose cancer has a specific change (mutation) known as KRAS G12D. The medicine aims to target and attack cancer cells with this mutation. It may be an option if standard treatments have stopped working or are not available.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Hear when a new Advanced Solid Tumors With MAPK Pathway Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.